

REMARKS

Claims 11-16, 21, 20 and 22 are active in the case. Reconsideration is respectfully requested.

The present invention is directed to piperazinylbenzothiazole compounds that are useful in the treatment of cerebral ischemic disorders and CNS disorders.

Claim Amendments

Claims 12-16 have been amended to recite a piperazinyl benzothiazole compound in the preamble of each claim. The amendment is believed to be sufficient to overcome the rejection under 35 USC 112 of these claims. Entry of the amendments into the record is respectfully requested.

Rejection, 35 USC 112, First Paragraph

Claim 21 has been amended by the limitation of the claim to the treatment of ischemia. It is noted that the Examiner comments on page 3, in the first full paragraph of commentary, that the specification is enabling of a method of treating ischemia, while apparently not enabling of the treatment of cerebral ischemic disorders or CNS disorders. Accordingly, applicants have amended Claim 21 to recite a method of treating ischemia only. It is therefore believed that the inventive aspect of Claim 21, as amended, overcomes the non-reference ground of rejection. Withdrawal of the rejection of the claim is respectfully requested.

Applicants wish to thank the Examiner for the indication of allowable subject matter in the case.

Appln No. 10/511,438
Reply to Office Action of May 3, 2007

It is now believed that the application is in proper condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Frederick D. Vastine
Registration Number 27,013

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413 -2220